The role of dissolution testing in complementary and African traditional medicines: development of methods and applications. Isadore (Izzy) Kanfer

Size: px
Start display at page:

Download "The role of dissolution testing in complementary and African traditional medicines: development of methods and applications. Isadore (Izzy) Kanfer"

Transcription

1 The role of dissolution testing in complementary and African traditional medicines: development of methods and applications Isadore (Izzy) Kanfer RHODES UNIVERSITY Where leaders learn DISSOLUTION WORKSHOP CHALLENGES IN DISSOLUTION TESTING: EQUIVALENCE AND SURROGATES 9-10 DECEMBER 2009 Barratt Lecture Complex, Rhodes University, Grahamstown South Africa, Dissolution Testing A QC Tool or Bioequivalence Predictor? 1

2 Dissolution This test is used to measure the release of an active substance (usually single ingredient) from the product in solid oral, tablet or capsule dosage forms. It is one of the most important and useful in vitro tests for assuring product quality In vitro dissolution often aids in guiding the selection of prototype formulations It helps to determine optimum amounts of ingredients needed to achieve requisite drug release profiles It is one of the most important and useful in vitro tests for assuring product quality batch-batch consistency Provides information on the impact of changes in composition, process or site of manufacture Can help identify potential problems of In vivo release and bioavailability/absorption following administration 2

3 In vitro dissolution is a valuable tool to assess drug product stability and shelf-life As products age, the formulation s properties may change and alter the dissolution characteristics of the product over time For example: 1) moisture levels may increase or decrease over time and this can result in altered tablet hardness and subsequent possible changes in drug release rates 2) Polymorphic transformations affect solubility and dissolution Disintegration Deaggregation Dissolution Drug in Blood 3

4 Factors Affecting Dissolution Rate Over the past 30 years or so, dissolution testing is probably the most important in vitro test that can be used to assess and control variables associated with formulation excipients, design and manufacturing which may alter the release characteristics of the active moiety from the dosage form. In vitro In vivo L Shargel and ABC Yu, Applied Biopharmaceutics & Pharmacokinetics, 4th Edition,

5 Banker et al, Lieberman and Lachman (eds)pharmaceutical Dosage Forms: Tablets Volume1, 1980 Banker et al, Lieberman and Lachman (eds)pharmaceutical Dosage Forms: Tablets Volume1,

6 Guidelines For Dissolution Testing of Oral Dosage Forms (Orthodox Medicines) Developed USA FDA (Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. U.S. Dept of Health and Human Services, Food & Drug Administration, Center for Drug Evaluation and research (CDER), Rockville, USA, 1977) FDA recommends use of buffers in the range for dissolution media and initial iti method development Unlike orthodox medicines, specific guidelines for dissolution testing of complementary/alternate (CAMs) and traditional medicines (TMs) have not been developed Also, there are no dissolution testing requirements for the quality control of such products. 6

7 Application of dissolution testing as a quality control tool in complementary & alternative medicines (CAMs) and traditional medicines (TMs) CAMs/TMs, unlike conventional pharmaceutical products, which usually consist of one or two well- characterized active ingredients, are complex, consisting of multiple components that may be active individually or in combination What should be measured? i.e. in contrast to chemically defined components, the actives in CAMs/TMs are generally defined to be the whole herbal preparation, e.g. the extract in its entirety Chemical composition and classification of active pharmaceutical ingredients (API s) in CAMs/TMs Suggested that since the whole herbal product, e.g. extract, is regarded as the API, several extract types, depending on the pharmaceuticalanalytical, pharmacological-toxicological and clinical findings, can be identified: A B1 B2 extracts containing constituents (single or groups) that are solely responsible for the activity (standardized extracts) extracts containing chemically defined constituents (single or groups) known to contribute to pharmacological or synergistic activity (quantified extracts) extracts containing no constituents documented as being determinant or relevant for efficacy, or having pharmacological or clinical relevance. 7

8 C unknown active ingredients for which no individual active ingredients have been identified but have a traditional place in therapy of certain diseases. Use of chemical markers which may not contribute to any activity, e.g. Valerian CASE STUDY St John s Wort Products Components in St John s Wort known, or suspected, to play a role in its antidepressant activity include phloroglucinols, naphthodianthrones and flavonoids, hence B1 category Hyperforin is purported to contribute to the antidepressive activity 8

9 Roles of other components in St John s Wort? e.g.naphthodianthrones (medium polarity)? Flavonoids (hydrophilic)? CONTENT UNIFORMITY and COMPLIANCE WITH THE LABEL CLAIM are standard quality criteria that need to be tested! What about dissolution testing? 5 St John s Wort products were selected by Westerhoff et al. (2002), J.Pharm Pharmacol., 54: Dissolution of hyperforin, naphthodianthrones (hypericin & pseudohypericin) and flavonoids (isoquercitrin, quercitrin, rutin and hyperoside) were characterized to cover the entire spectrum of polarities present in the products. FaSSIF=Fasted state simulated intestinal fluid; ph 6.5 FeSSIF=Fed state simulated intestinal fluid; ph 5.0 SGF=Simulated gastric fluid; ph 1.5 Westerhoff et al; (2002), J Pharm Pharmacol; 54;

10 Westerhoff et al; (2002), J Pharm Pharmacol; 54; Biflavonoid Purported to be pharmacologically active. 10

11 Coated tablet (St.John s Wort) Tap water? N.B. Phenolic glycosides better dissolved than flavone aglycones Jürgenliemk and Nahrstedt 11

12 Pharmacological synergism and/or Physicochemical synergism? Flavonoids (other included components) increase dissolution of hypericin? What about synergistic effects on bioavailability? Pharmaceutical quality of different Ginkgo biloba brands Kressmann et al; J Pharm Pharmacol; 54: (2002) 12

13 Consider African Potato (AP): a commonly used African Traditional Medicine (ATM) Apart from its perceived nutritional value used for: Immuno-boosting properties urinary diseases prostrate hypertrophy cancer? In South Africa African Potato gained prominence as an alternative medicine for nutritional use in the daily diet of HIV/AIDS patients recommended by the previous South African Minister of Health 13

14 AP contains as it s most important component, a norlignan di-glucoside, namely hypoxoside It is also purported to contain a sterol, β-sitosterol (BSS) Currently, assay methods for quality control of AP products include: Hypoxoside (HPLC UV 1 and dcze 2 ) 1 Nair & Kanfer, J Agric Food Chem, 54: , Nair & Kanfer, Phytochem Anal, 18: , 2007 Stigmasterol, β-sitosterol and stigmastanol (HPLC with evaporative light-scattering detection 3 ) 3 Nair, Kanfer & Hoogmartens, J Pharm Biomed Anal, 41: ,

15 Approaches used for the development of a suitable dissolution method for products containing AP: Phytochemical composition? - Hypoxoside - Sterols & sterolins but which? First step = Assay! Assay results: β-sitosterol major component Hypoxoside Used as markers for Quality Control 15

16 List of AP Products: Initial dissolution tests: Products A,B,D,E,F & G - all capsules USP-1 (Basket) Product C - the only tablet t dosage form - USP-2 (Paddle) Dissolution Conditions: Volume 900 ml Rotation speed 100 rpm Temperature 37 ± 0.5 ºC Dissolution media as per USA FDA Guidance buffered dissolution media (ph ) 16

17 Hypoxoside relatively unstable at higher phs, hence used acidic dissolution media only, i.e. ph 1.2 and 4.5 Product B used since it contained highest content of hypoxoside β-sitosterol relatively insoluble in aqueous media Dissolution performed at phs 1.2, 4.5, 6.8 and 7.8 NO β-sitosterol detected even after 12 hours - i.e confirmation of aqueous insolubility Choice of alternate dissolution media necessary FaSSIF (fasted state simulation - generally ph 6.5) FeSSIF (fed state simulation - generally ph 5.0) 17

18 Dissolution of product D for BSS in FaSSIF & FeSSIF at various phs Dissolution comparison of Products A, B and C at ph

19 Dissolution profiles of Products D, E, F & G showing profiles of BSS at ph 5.0 in FeSSIF Issues with African Traditional Medicines (ATMs) Sceletium Species - example 19

20 Reference substances: Example Sceletium Alkaloids OCH 3 OCH 3 OCH 3 OCH 3 5' 4' 3' OCH3 OCH3 OCH3 OCH3 3 6' 1' 3a 2' 4 5 HCl 2 N 6 7a 7 O N O N O N O CH 3 CH 3 CH 3 Mesembrine (Major alkaloid) 7 Mesembrenone Mesembrenone CH 3 Mesembrine hydrochloride crystals OCH 3 OCH 3 OCH3 OCH3 OCH 3 OCH3 N CH 3 H OH N CH 3 H OH N CH3 H OH Mesembranol crystals Epimesembranol Mesembrenol Dissolution profile of Sceletium capsules in Buffer ph Mean P rofiles AP 0001/09 Test Product Sceletium C apsule NNNNN % Released Time (Hours) 20

21 Summary Complexity of CAMS/TMs Role of dissolution as a quality control tool for CAMS/TMs What to monitor? Bio-relevance of dissolution testing? 21

Overview of Dissolution for BA/BE

Overview of Dissolution for BA/BE Biopharmaceutics Classification System based on Solubility/Permeability Biowaivers for BCS I Drugs Discussion of BCS III Drugs Models establishing in vivo-in vitro Correlations (IVIVC Levels A-C) 1 Biopharmaceutics

More information

Bundesinstitut für Arzneimittel und Medizinprodukte. Dissolution Testing. Analytik,Methodenentwicklung, Bioäquivalenz SAQ. Olten, 25.

Bundesinstitut für Arzneimittel und Medizinprodukte. Dissolution Testing. Analytik,Methodenentwicklung, Bioäquivalenz SAQ. Olten, 25. Dissolution Testing Analytik,Methodenentwicklung, Bioäquivalenz SAQ Olten, 25. Januar 2006 Dr. H. Potthast (h.potthast@bfarm.de) 1 2 Basis for Biowaiver Applications/Decisions Note for Guidance on the

More information

Generic drugs are copies of innovator drug products

Generic drugs are copies of innovator drug products dx.doi.org/10.14227/dt190412p51 In Vitro Equivalence Studies of Generic Metformin Hydrochloride Tablets and Propranolol Hydrochloride Tablets Under Biowaiver Conditions in Lagos State, Nigeria e-mail:

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

Revision of The Dissolution Procedure: Development and Validation 1092

Revision of The Dissolution Procedure: Development and Validation 1092 Page 1 of 5 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Revision of The Dissolution Procedure: Development and Validation

More information

Guidance for Industry

Guidance for Industry #171 Guidance for Industry Waivers of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products and Type A Medicated Articles (This version of the guidance replaces

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 29 July 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON QUALITY OF MODIFIED

More information

Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules

Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This

More information

Bioequivalence Testing, using the Dissolution Profile

Bioequivalence Testing, using the Dissolution Profile Determining Similarity of Products- F 2 Criterion and Variability of Dissolution Test Vivian Gray V. A. Gray Consulting Dissolution Workshop December 10, 2010 Bioequivalence Testing, using the Dissolution

More information

2.3 QUALITY OVERALL SUMMARY Sakura Tablet

2.3 QUALITY OVERALL SUMMARY Sakura Tablet English Mock QOS P2_Final_June08 MODULE 2: COMMON TECHNICAL DOCUMENT SUMMARIES Generic name: Amokinol 2.3 QUALITY OVERALL SUMMARY Sakura Tablet 1 English Mock QOS P2 Final TABLE OF CONTENTS Page Table

More information

Asian Journal of Research in Biological and Pharmaceutical Sciences Journal home page: www.ajrbps.com

Asian Journal of Research in Biological and Pharmaceutical Sciences Journal home page: www.ajrbps.com Research Article ISSN: 2349 4492 Asian Journal of Research in Biological and Pharmaceutical Sciences Journal home page: www.ajrbps.com IMPROVEMENT OF SOLUBILITY OF OMEPRAZOLE MAGNESIUM BY SOLID DISPERSION

More information

Alharith Hassan. Q 10 Method of Shelf-life estimation. Methods of Chemical stabilisation 11/20/2015

Alharith Hassan. Q 10 Method of Shelf-life estimation. Methods of Chemical stabilisation 11/20/2015 Q 10 Method of Shelf-life estimation Q 10 approach is an old concept that could be useful for estimating the shelf-life at room temperature of products recommended for cold storage. Calculations are based

More information

PRODUCT DEVELOPMENT GUIDE

PRODUCT DEVELOPMENT GUIDE PRODUCT DEVELOPMENT GUIDE PRE-FORMULATION - TABLETS Introduction Guidelines for the development of a ANDA product for the US market, Note: some tests or procedures may be unnecessary. The order of performing

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation

More information

Absorption of Drugs. Transport of a drug from the GI tract

Absorption of Drugs. Transport of a drug from the GI tract Absorption of Drugs Absorption is the transfer of a drug from its site of administration to the bloodstream. The rate and efficiency of absorption depend on the route of administration. For IV delivery,

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry DRAFT GUIDANCE This guidance

More information

EXIGENCIA DE ESTUDIOS DE BIOEQUIVALENCIA A TRAVÉS DE METODOS IN VITRO

EXIGENCIA DE ESTUDIOS DE BIOEQUIVALENCIA A TRAVÉS DE METODOS IN VITRO EXIGENCIA DE ESTUDIOS DE BIOEQUIVALENCIA A TRAVÉS DE METODOS IN VITRO Q.F. ALEXIS ACEITUNO, PhD Jefe Subdepto. Biofarmacia & Bioequivalencia Agencia Nacional de Medicamentos Instituto de Salud Pública

More information

It is an important tool to assess factors that affect the bioavailability of a drug from a solid preparartion.

It is an important tool to assess factors that affect the bioavailability of a drug from a solid preparartion. Quality control of tablets Dissolution It is an important tool to assess factors that affect the bioavailability of a drug from a solid preparartion. To ensure that the preparation comply with product

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations U.S. Department of Health and Human Services Food and Drug Administration Center

More information

IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION

IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION I. For Calcium Acetate Drug Products Table I.1 Submission Summary * Drug Product Name Strength(s)

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Food, Medicine and Health Care Administration and Control Authority

Food, Medicine and Health Care Administration and Control Authority Food, Medicine and Health Care Administration and Control Authority Bio equivalence Study Registration Requirements in Ethiopia (Four Countries Experience) Mengistab W.Aregay (Bpharm, MSc. in Health Monitoring

More information

Introduction to Enteris BioPharma

Introduction to Enteris BioPharma Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based

More information

Comparative Assessment of the Quality Control Measurements of Multisource Ofloxacin Tablets Marketed in Nigeria

Comparative Assessment of the Quality Control Measurements of Multisource Ofloxacin Tablets Marketed in Nigeria dx.doi.org/10.14227/dt170210p20 Comparative Assessment of the Quality Control Measurements of Multisource Ofloxacin Tablets Marketed in Nigeria e-mail: jdjide@yahoo.com Sunday O. Awofisayo 1, *, Oladoja

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):892-898 World Health Organization s Guidelines for

More information

BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use.

BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use. BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use. USP proposes the revision and development of a suite of plastic packaging system standards in the current issue of PF. General test chapter

More information

Quality by Design for ANDAs: An Example for Modified Release Dosage Forms

Quality by Design for ANDAs: An Example for Modified Release Dosage Forms Quality by Design for ANDAs: An Example for Modified Release Dosage Forms Introduction to the Example This is an example pharmaceutical development report illustrating how ANDA applicants can move toward

More information

QbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance

QbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance QbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance Dr Amina Faham (Dow), Dr Liz Meehan (AstraZeneca) ExcipientFest, Amsterdam NL June 24, 2014 What do you understand

More information

European Continuing Education College

European Continuing Education College Design and Development of Conventional and Modified Release Oral Drug Delivery Systems Three Day Intensive Course for Managers, Scientists and Technicians with the Emphasis on the Principles of Oral Drug

More information

Introduction to pharmaceutical technology

Introduction to pharmaceutical technology Introduction to pharmaceutical technology Marie Wahlgren Chapter 1 What is the topics of today Introduction to the course Introduction to the project assignment How to choose a new drug formulation 1 Contacts

More information

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,

More information

Importing pharmaceutical products to China

Importing pharmaceutical products to China Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval

More information

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER DISCUSSION IN THE HMPWG 2003-2005 RELEASE FOR CONSULTATION December 2005 DEADLINE

More information

2014 Annual Report on Inspections of Establishments

2014 Annual Report on Inspections of Establishments 2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered

More information

Guideline on stability testing for applications for variations to a marketing authorisation

Guideline on stability testing for applications for variations to a marketing authorisation 21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications

More information

Tamsulosin Hydrochloride Capsules

Tamsulosin Hydrochloride Capsules . nal Revision Bulletin Official October 1, 2011 Tamsulosin 1 standard solution, and shake well. Centrifuge at 1500 rpm for 10 min, and use the supernatant, passing it if Tamsulosin Hydrochloride Capsules

More information

Prescription drug products stability and expiration dates*

Prescription drug products stability and expiration dates* Prescription drug products stability and expiration dates* UTMB/NASA-JSC Aerospace Medicine Grand Rounds Houston, TX October 27, 2009 Mansoor A. Khan, R.Ph., Ph.D. Director, FDA/CDER/Division of Product

More information

Drug dissolution (or release) testing is an analytical

Drug dissolution (or release) testing is an analytical dx.doi.org/10.14227/dt130406p18 Developing Discriminatory Drug Dissolution Tests and Profiles: Some Thoughts for Consideration on the Concept and Its Interpretation Saeed A. Qureshi, Ph.D. 1 e-mail: saeed_qureshi@hc-sc.gc.ca

More information

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES February 2013 RESTRICTED GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES DRAFT FOR COMMENT Should you have any comments on the attached text, please send these to Dr Sabine Kopp, Manager, Medicines

More information

Biorelevant media are artificial in vitro media designed

Biorelevant media are artificial in vitro media designed dx.doi.org/10.14227/dt200313p44 Comparison of the Solubility and Dissolution of Drugs in Fasted- State Biorelevant Media (FaSSIF and ) Contact: www.biorelevant.com/contact Mathew Leigh*, Bastian Kloefer,

More information

Solid dosage forms testing: Disintegration test and tablet friability and hardness

Solid dosage forms testing: Disintegration test and tablet friability and hardness Specialized Laboratory for Drug production (N111049) Instructions Solid dosage forms testing: Disintegration test and tablet friability and hardness Tutor: Ing. Jiří Petrů Study program: Drug synthesis

More information

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/380/95 ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

More information

Robert L. Talbert, Pharm. D. College of Pharmacy UT Austin. UT Health Science Center San Antonio

Robert L. Talbert, Pharm. D. College of Pharmacy UT Austin. UT Health Science Center San Antonio Therapeutic Substitution Robert L. Talbert, Pharm. D. College of Pharmacy UT Austin School of Medicine UT Health Science Center San Antonio Therapeutic Equivalence-Related Terms Approved Drug Products

More information

Compilation of individual product-specific guidance on demonstration of bioequivalence

Compilation of individual product-specific guidance on demonstration of bioequivalence 17 December 2014 EMA/CHMP/736403/2014 Committee for Medicinal Products for Human Use (CHMP) Compilation of individual product-specific guidance on demonstration of bioequivalence Initial batch of individual

More information

Workshop A Design Space (DS)

Workshop A Design Space (DS) Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information

More information

Challenges in the Development of Micronutrient-rich Food Ingredients from Soya Beans and Moringa Oleifera Leaves

Challenges in the Development of Micronutrient-rich Food Ingredients from Soya Beans and Moringa Oleifera Leaves Abstract Challenges in the Development of Micronutrient-rich Food Ingredients from Soya Beans and Moringa Oleifera Leaves Leonard M. P. Rweyemamu Department of Chemical & Process Engineering University

More information

Workshop B Control Strategy

Workshop B Control Strategy ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation

More information

Performance Evaluation of Actimask 92S Ibuprofen: A Novel Taste-Masked Ibuprofen for Use in Orally-Dispersible Dosage Forms

Performance Evaluation of Actimask 92S Ibuprofen: A Novel Taste-Masked Ibuprofen for Use in Orally-Dispersible Dosage Forms Performance Evaluation of Actimask 92S Ibuprofen: A Novel Taste-Masked Ibuprofen for Use in Orally-Dispersible Dosage Forms Author: Brian D. Wilson Background Recently, orally-dispersible dosage forms,

More information

Guideline on dossier requirements for Type IA and IB notifications

Guideline on dossier requirements for Type IA and IB notifications Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations

More information

Formulation and Evaluation of Didanosine Enteric Coated Sustained Release Tablet

Formulation and Evaluation of Didanosine Enteric Coated Sustained Release Tablet Formulation and Evaluation of Didanosine Enteric Coated Sustained Release Tablet K. L. Senthil Kumar*, S. Ashokkumar, R. P. Ezhilmuthu Dept of Pharmaceutics, Padmavathi College of Pharmacy and Research

More information

Unedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010

Unedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010 GUIDELINE ON SUBMISSION OF DOCUMENTATION FOR A MULTISOURCE (GENERIC) FINISHED PHARMACEUTICAL PRODUCT (FPP): PREPARATION OF PRODUCT DOSSIERS (PDS) IN COMMON TECHNICAL DOCUMENT (CTD) FORMAT Unedited version

More information

Evaluation of Dissolution Hydrodynamics in the USP, Peak and Flat-Bottom Vessels Using Different Solubility Drugs

Evaluation of Dissolution Hydrodynamics in the USP, Peak and Flat-Bottom Vessels Using Different Solubility Drugs dx.doi.org/10.14227/dt120105p11 Evaluation of Dissolution Hydrodynamics in the USP, Peak and Flat-Bottom Vessels Using Different Solubility Drugs Tahseen Mirza, Ph.D., Yatindra Joshi, Ph.D, Qian (Julie)

More information

PHARMACEUTICAL DEVELOPMENT

PHARMACEUTICAL DEVELOPMENT INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL DEVELOPMENT Q8(R2) Current Step

More information

Annex 9 Guide to good storage practices for pharmaceuticals 1

Annex 9 Guide to good storage practices for pharmaceuticals 1 World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities

More information

QUALITY BY DESIGN (QBD) : A COMPLETE REVIEW

QUALITY BY DESIGN (QBD) : A COMPLETE REVIEW Review Article QUALITY BY DESIGN (QBD) : A COMPLETE REVIEW Nishendu P. Nadpara*, Rakshit V. Thumar, Vidhi N. Kalola, Parula B. Patel Department of Quality Assurance, S. J. Thakkar Pharmacy College, Opp.

More information

GDUFA Regulatory Science Update

GDUFA Regulatory Science Update GDUFA Regulatory Science Update Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA GPhA Annual Meeting Feb 9, 2015 Goals

More information

Annex 6. Guidance on variations to a prequalified product dossier. Preface

Annex 6. Guidance on variations to a prequalified product dossier. Preface Annex 6 Guidance on variations to a prequalified product dossier Preface This guidance document was technically and structurally inspired by the Guideline on dossier requirements for type IA and IB notifi

More information

Public Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007

Public Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Public Assessment Report Scientific discussion Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Applicant: E Consult ApS, Denmark This module reflects the

More information

Table 1. Pure superdisintegrant tablet formulation. Material % w/w Weight (mg) Superdisintegrant 99 277.2 Stearic acid 1 2.

Table 1. Pure superdisintegrant tablet formulation. Material % w/w Weight (mg) Superdisintegrant 99 277.2 Stearic acid 1 2. PHARMACEUTICAL TECHNOLOGY REPORT Ashland Specialty Ingredients ashland.com PTR-95 Page 1 of 5 Utility of Polyplasdone as a Tablet Binder Quyen Schwing, Marvin Davis, Divya Tewari, Thomas Dürig Ashland

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited

More information

A FDA Perspective on Nanomedicine Current Initiatives in the US

A FDA Perspective on Nanomedicine Current Initiatives in the US A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification

More information

Bioequivalence Study Design Considerations. Dr. John Gordon

Bioequivalence Study Design Considerations. Dr. John Gordon Bioequivalence Study Design Considerations Dr. John Gordon Key Output of Programme A list of prequalified medicinal products used for treatment of HIV/AIDS, malaria, tuberculosis, influenza, and for reproductive

More information

ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING

ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING For More Information on Submission of an ANDA in Electronic Common Technical Document (ectd) Format

More information

EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS

EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS BIOGRAPHICAL NOTE Kurt Moyer, Ph.D. Director of Research, NSF Pharmalytica Bristol, Connecticut, USA 06010 Tel: 1(860)

More information

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved Antiretrovirals for the Treatment of HIV U.S. Department of Health and Human Services

More information

Review Considerations for Transdermal Patches. Bhagwant Rege, Ph.D. Office of Generic Drugs Division of Chemistry I

Review Considerations for Transdermal Patches. Bhagwant Rege, Ph.D. Office of Generic Drugs Division of Chemistry I Review Considerations for Transdermal Patches Bhagwant Rege, Ph.D. Office of Generic Drugs Division of Chemistry I 1 Disclaimer Opinions expressed in this presentation are those of the speaker and do not

More information

Liposome Drug Products

Liposome Drug Products Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry DRAFT GUIDANCE This guidance document is being

More information

POLYOX. Application Data

POLYOX. Application Data POLYOX Application Data Water Soluble Resins The Influence of In Vitro Dissolution Method on the Release of a Highly Water Soluble Drug from Polyethylene Oxide and Hypromellose Hydrophilic Extended Release

More information

Veterinary Compounding

Veterinary Compounding Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),

More information

ANALYTICAL METHOD DEVELOPMENT FOR DISSOLUTION RELEASE OF FINISHED SOLID ORAL DOSAGE FORMS

ANALYTICAL METHOD DEVELOPMENT FOR DISSOLUTION RELEASE OF FINISHED SOLID ORAL DOSAGE FORMS Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 4, Issue 2, 2012 Research Article ANALYTICAL METHOD DEVELOPMENT FOR DISSOLUTION RELEASE OF FINISHED SOLID

More information

PREPARATION AND EVALUATION OF STARCH PHOSPHATE- A NEW MODIFIED STARCH AS A DISINTEGRANT IN TABLET FORMULATIONS

PREPARATION AND EVALUATION OF STARCH PHOSPHATE- A NEW MODIFIED STARCH AS A DISINTEGRANT IN TABLET FORMULATIONS Int. J. Chem. Sci.: 9(2), 2011, 889-899 Int. J. Chem. Sci.: ISSN 9(1), 0972-768X 2011, 1-11 www.sadgurupublications.com PREPARATIN AND EVALUATIN F STARCH PHSPHATE- A NEW MDIFIED STARCH AS A DISINTEGRANT

More information

Acids & Bases: Using Purple Cabbage as a ph indicator. Grade 9 Activity Plan

Acids & Bases: Using Purple Cabbage as a ph indicator. Grade 9 Activity Plan Acids & Bases: Using Purple Cabbage as a ph indicator Grade 9 Activity Plan 1 Acids, Bases & Purple Cabbage Objectives: 1. To demonstrate the basic physical and chemical properties of acids and bases.

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document

More information

Guide to Inspections of Tablet Manufacturing Facilities including Pre/Post Approval Issues as per USFDA

Guide to Inspections of Tablet Manufacturing Facilities including Pre/Post Approval Issues as per USFDA International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.4, No.1, pp 49-55, Jan-Mar 2012 Guide to Inspections of Tablet Manufacturing Facilities including Pre/Post Approval

More information

Public Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark

Public Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark Public Assessment Report Scientific discussion Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676 Applicant: E Consult ApS, Denmark This module reflects the scientific discussion for the approval

More information

The Effect of Coating Process Conditions and Coating Formula Type on the Quantity and Location of Water in Film Coated Tablets

The Effect of Coating Process Conditions and Coating Formula Type on the Quantity and Location of Water in Film Coated Tablets OPADRY II Application Data High Performance Film Coating System The Effect of Coating Process Conditions and Coating Formula Type on the Quantity and Location of Water in Film Coated Tablets OBJECTIVES

More information

BIOAVAILABILITY & BIOEQUIVALENCE TRIALS

BIOAVAILABILITY & BIOEQUIVALENCE TRIALS BIOAVAILABILITY & BIOEQUIVALENCE TRIALS Shubha Rani,, Ph.D. Technical Director & Head-Biometrics and Data Management Synchron Research Services Pvt. Ltd. Ahmedabad 380 054 drshubha@synchronresearch.com

More information

The United States Pharmacopeia

The United States Pharmacopeia INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29 February to 2 March 2012 The United States Pharmacopeia Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Roger L.

More information

Overview of Drug Development: the Regulatory Process

Overview of Drug Development: the Regulatory Process Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger

More information

AMBERLITE IRP64 Pharmaceutical Grade Cation Exchange Resin (Polacrilex Resin)

AMBERLITE IRP64 Pharmaceutical Grade Cation Exchange Resin (Polacrilex Resin) AMBERLITE IRP64 Pharmaceutical Grade Cation Exchange Resin (Polacrilex Resin) Description AMBERLITE IRP64 [1] resin is an insoluble, weakly acidic, hydrogen form, cation exchange resin supplied as a dry,

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure TELMISARTAN DR REDDY S 20 MG TABLETS TELMISARTAN DR REDDY S 40 MG TABLETS TELMISARTAN DR REDDY S 80 MG TABLETS (telmisartan) Procedure No: UK/H/5034/001-003/DC

More information

Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration

Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration Disclaimer & Disclosure Views presented are those of the

More information

PL 17871/0208 UKPAR TABLE OF CONTENTS

PL 17871/0208 UKPAR TABLE OF CONTENTS Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

Draft agreed by Pharmacokinetics Working Party January 2011. Adoption by CHMP for release for consultation 17 February 2011

Draft agreed by Pharmacokinetics Working Party January 2011. Adoption by CHMP for release for consultation 17 February 2011 17 November 2011 EMA/CHMP/600958/2010/Corr.* Committee of Medicines for Human Use (CHMP) Appendix IV of the Guideline on the Investigation on Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of

More information

CypExpress 3A4 Catalyzed Conversion of Testosterone (TE) to 6β- Hydroxytestosterone (HT)

CypExpress 3A4 Catalyzed Conversion of Testosterone (TE) to 6β- Hydroxytestosterone (HT) TM CASE STUDY CypExpress 3A4 Catalyzed Conversion of to Shuvendu Das, 1 Enrique Martez, 2 and Mani Subramanian 1 1 Center for Biocatalysis and Bioprocessg, University of Iowa 2 Oxford Biomedical Research,

More information

QUALITY, SAFETY AND EFICACY ASSESSOR

QUALITY, SAFETY AND EFICACY ASSESSOR Curriculum vitae PERSONAL INFORMATION Javier Alonso Naveda WORK EXPERIENCE March 2014 Present SUPPORT CVMP MEMBER, CENTRALIZED MANAGEMENT PROCEDURES, REFERRALS, QRD, QUALITY ASSESSOR Support to the CVMP

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE

More information

6 Characterization of Casein and Bovine Serum Albumin

6 Characterization of Casein and Bovine Serum Albumin 6 Characterization of Casein and Bovine Serum Albumin (BSA) Objectives: A) To separate a mixture of casein and bovine serum albumin B) to characterize these proteins based on their solubilities as a function

More information

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar

More information

Directly compressed mini-tablets coated in a solid-wall pan for sustained drug release

Directly compressed mini-tablets coated in a solid-wall pan for sustained drug release Directly compressed mini-tablets coated in a solid-wall pan for sustained drug release March 2012 N. Passerini, B. Albertini, L.Rodriguez Department of Pharmaceutical Sciences, University of Bologna C.

More information

A Stability Program for the Distribution of Drug Products

A Stability Program for the Distribution of Drug Products A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained

More information

Development and examination of solubility measurement methods for drug solubility determination

Development and examination of solubility measurement methods for drug solubility determination Development and examination of solubility measurement methods for drug solubility determination Thesis of doctoral (PhD) dissertation Edit Baka Semmelweis University Doctoral School of Pharmaceutical and

More information

CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS

CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS Overview 6.1 This chapter sets out the Review Committee s findings and recommendations on procurement

More information

Determination of Thermodynamic Solubility of Active Pharmaceutical Ingredients for Veterinary Species: A New USP General Chapter

Determination of Thermodynamic Solubility of Active Pharmaceutical Ingredients for Veterinary Species: A New USP General Chapter Vol. 41(3) [May June 2015] (P) \\uspnetapp2\share\share\uspnf\printq\pager\xmlin\lyc_20150317125905_s201364.xml Mar. 17, 2015 12:59:07 Keyword: Level1 and Level2 keywords not present STIMULI TO THE REVISION

More information

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. European Medicines Agency May 2000 CPMP/ICH/367/96 ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications Comments and suggestions regarding this document should be submitted within 90 days of publication in the

More information